Novocure elects Kristin Stafford to board of directors

NovoCure Ltd

Kristin Stafford elected to Novocure board effective March 28, 2023.
She is SVP, Chief Accounting Officer at Royalty Pharma plc.
She receives option grant of $667,000 fair value, vesting over three years.
She joins Compensation Committee.

item 5.02 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Appointed

Kristin Stafford

director

NVCR · NovoCure Ltd

Effective: 2023-03-28
Filed: March 29, 2023, 7:59 PM ET

On March 28, 2023 , the Board of Directors (the “Board”) of NovoCure Limited (the "Company") elected Kristin Stafford as a director of the Company, effective immediately, increasing the size of the Board to ten members.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Kristin Stafford was elected as director at NovoCure Ltd.

Action: elected
Role: director

Exact text from the filing

On March 28, 2023 , the Board of Directors (the “Board”) of NovoCure Limited (the "Company") elected Kristin Stafford as a director of the Company, effective immediately, increasing the size of the Board to ten members.

View on SEC.gov

NovoCure Ltd filing history →

Source: SEC EDGAR

accession 0001645113-23-000032

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.